Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-16
2011-08-16
Powers, Fiona T (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255050, C514S269000, C514S278000, C514S361000, C514S397000, C514S409000, C544S141000, C544S315000, C544S405000, C546S015000, C548S127000, C548S314700, C548S410000
Reexamination Certificate
active
07998959
ABSTRACT:
The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 such as obesity and diabetes.
REFERENCES:
patent: 4076819 (1978-02-01), Maffrand
patent: 4439606 (1984-03-01), Du et al.
patent: 5442064 (1995-08-01), Pieper et al.
patent: 5614534 (1997-03-01), Binet et al.
patent: 5633247 (1997-05-01), Baldwin et al.
patent: 5668138 (1997-09-01), Baziard-Mouysset et al.
patent: 5852029 (1998-12-01), Fisher et al.
patent: 5981754 (1999-11-01), Badone et al.
patent: 6355617 (2002-03-01), Luke et al.
patent: 6547958 (2003-04-01), Elomari et al.
patent: 7304081 (2007-12-01), Yao et al.
patent: 2003/0229119 (2003-12-01), Kym et al.
patent: 2005/0020645 (2005-01-01), Ohta et al.
patent: 2005/0080078 (2005-04-01), Aquila et al.
patent: 2005/0282858 (2005-12-01), Yao et al.
patent: 2005/0288317 (2005-12-01), Yao et al.
patent: 2005/0288329 (2005-12-01), Yao et al.
patent: 2005/0288338 (2005-12-01), Yao et al.
patent: 2006/0004049 (2006-01-01), Yao et al.
patent: 2006/0009471 (2006-01-01), Yao et al.
patent: 2006/0009491 (2006-01-01), Yao et al.
patent: 2006/0019977 (2006-01-01), Habashita et al.
patent: 2006/0106045 (2006-05-01), Hughes et al.
patent: 2006/0116382 (2006-06-01), Yao et al.
patent: 2006/0122197 (2006-06-01), Yao et al.
patent: 2006/0122210 (2006-06-01), Yao et al.
patent: 2006/0149070 (2006-07-01), Rohde et al.
patent: 2006/0199816 (2006-09-01), Gillespie et al.
patent: 2007/0066584 (2007-03-01), Yao et al.
patent: 2007/0129345 (2007-06-01), Zhuo et al.
patent: 2007/0197530 (2007-08-01), Li et al.
patent: 2007/0208001 (2007-09-01), Zhuo et al.
patent: 2007/0213311 (2007-09-01), Li et al.
patent: 2007/0270424 (2007-11-01), Li et al.
patent: 2007/0293529 (2007-12-01), Li et al.
patent: 2623567 (1976-12-01), None
patent: 1683797 (2006-07-01), None
patent: 4334357 (1992-11-01), None
patent: WO 02/06868 (2002-01-01), None
patent: WO 03037847 (2003-05-01), None
patent: WO 03/045912 (2003-06-01), None
patent: WO 03/053915 (2003-07-01), None
patent: WO 03/104207 (2003-12-01), None
patent: WO 2004056745 (2004-07-01), None
patent: WO 2004065351 (2004-08-01), None
patent: WO 2004/082687 (2004-09-01), None
patent: WO 2004089470 (2004-10-01), None
patent: WO 2004089896 (2004-10-01), None
patent: WO 2004/096139 (2004-11-01), None
patent: WO 2005047286 (2005-05-01), None
patent: WO 2005060963 (2005-07-01), None
patent: WO 2005063745 (2005-07-01), None
patent: WO 2005108359 (2005-11-01), None
patent: WO 2006/020598 (2006-02-01), None
patent: WO 2006012226 (2006-02-01), None
patent: WO 2006/040329 (2006-04-01), None
patent: WO 2006/047196 (2006-05-01), None
Hughes et al., “Total Synthesis of (−) Amathaspiramide F”, Angew. Chem. Int. Ed., 41(23), 4556-4559, 2002.
Hughes et al., “The total synthesis of (−)-Amathaspiramide F**”,Angewandte Chemie, Int 'l. Ed.,41(23), 4556-4559; 2002.
Morris et al., “Amathaspiramides A-F, Novel Brominated Alkaloids from the Marine BryozoanAmathia wilsoni”, Journal of Natural Products, 62(5), 688-693, 1999.
Xu et al., “Synthesis of Aza/Oxaspiro-γ-lactams by Radical Translocation Cyclization Reactions”,Synlett, (12), 1865-1868, 2005.
International Search Report and Written Opinion for International Appln. No. PCT/US2007/000695 dated Jan. 31, 2008 (15 pgs.).
International Preliminary Report on Patentability for International Appln. No. PCT/US2007/000695 dated Jul. 15, 2008 (9 pgs.).
Alberts et al. Endocrinology (2003) 144: 4755-4762.
Albiston et al. (1994) Mol. Cell. Endocrin. 105: R11-R17.
Barf et al. (2002) J. Med. Chem. 45: 3813-3815.
Bellows et al. (1998) Bone 23: 119-125.
Bhargava et al., (2001), Endo 142: 1587-1594.
Billaudel and Sutter (1979) Horm. Metab. Res. 11: 555-560.
Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
Blum, et al., (2003) Prog. Nucl. Acid Res. Mol. Biol. 75:173-216.
Bujalska et al. (1997) Lancet 349: 1210-1213.
Canalis (1996) J. Clin. Endocrinol. Metab. 81: 3441-3447.
Conn, (1955), J. Lab. Clin. Med. 45: 6-17.
Cooper et al. (2000) Bone 27: 375-381.
Database CAPLUS on STN (Columbus, OH, USA) No. 108:131815, Preparation and testing of f7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones as phosphodiesterase and bloodplatelet aggregation inhibitors, abstract, Meanwell, et al. (1988).
Database CAPLUS on STN (Columbus, OH, USA) No. 118:255342, {re[artopm pf M-heterpcuc;u;carbpmu;a,omp acids and analogs as prolylendopeptidase inhibotors' abstract, Hosoda et al. (1993).
Database CAPLUS on STN (Columbus, OH, USA) No. 126:317635, “Alpha-amino acids derived from ornithine as building blocks for peptide synthesis” abstract, Gescrinier et al. j. Pep. Res. 49(2):183-189 (1997).
Database CAPLUS on STN (Columbus, OH, USA) No. 143:78479, “Preparation of amino acid derivatives as novel M3 muscarinic acetylcholine receptor antagonists” abstract, Busch et al. (2005).
Davani et al. (2000) J. Biol. Chem. 275: 34841-34844.
Draper et al. (2003) Nat. Genet. 34: 434-439.
Edwards et al. (1988) Lancet 2: 986-989.
Engeli, et al., (2004) Obes. Res. 12: 9-17.
Funder et al. (1988), Science 242: 583-585.
Greene, et al., Protective Groups in Organic Synthesis, 2d. Ed., Wiley & Sons, 1991.
Gu et al., “Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11β-HSD1: Novel therapeutic agents for the treatment of metabolic syndrome,”Bioorg. Med. Chem. Lett.,15:5266-5269 (2005).
Hermanowski-Vosatka et al. (2005) J. Exp. Med. 202: 517-527.
Jausons-Loffreda et al. J. Biolumin and Chemilumin, 9:217-221 (1994).
Journal of Pharmaceutical Science, 66, 2 (1977).
Kotelevstev et al. (1997) Proc. Natl. Acad. Sci. 94: 14924-14929.
Kurukulasuriya , et al., (2003) Curr. Med. Chem. 10: 123-53.
Leonardi et al., “Synthesis, Pharmacological Evaluation, and Structure—Activity Relationship and Quantitative Structure—Activity Relationship Studies on Novel Derivatives of 2,4-Diamino-6,7-dimethoxyquinazoline α1-Adrenoceptor Antagonists,”J. Med. Chem.,42:427-437 (1999).
Lindsay et al. (2003) J. Clin. Endocrinol. Metab. 88: 2738-2744.
Livingstone et al. (2000) Endocrinology 131: 560-563.
Low et al. (1994) J. Mol. Endocrin. 13: 167-174.
Lupien et al. (1998) Nat. Neurosci. 1: 69-73.
Mallams et al., “Inhibitors of Farnesyl Protein Transferase. 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-Chloro-6,11-dihydro-5H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11- y1)piperazine and 1-(3-Bromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11- y1)piperazine,”J. Med. Chem.,41:877-893 (1998).
Masuzaki et al. (2001) Science 294: 2166-2170.
Masuzaki et al. (2003) J. Clinical Invest. 112: 83-90.
Masuzaki, et al., (2003) Curr. Drug Targets Immune Endocr. Metabol. Disord. 3: 255-62.
Matsuzawa et al. (1999) Ann. N.Y. Acad. Sci. 892: 146-154.
McEwen and Sapolsky (1995) Curr. Opin. Neurobiol. 5: 205-216.
Miller and Chrousos (2001) Endocrinology and Metabolism, eds. Felig and Frohman (McGraw-Hill, New York), 4th Ed.: 387-524.
Moeller et al., “Anodic Amide Oxidations in the Presence of Electron-Rich Phenyl Rings: Evidence for an Intramolecular Electron-Transfer Mechanism,”J. Org. Chem.,56:1058-1067 (1991).
Morton et al. (2001) J. Biol. Chem. 576: 41293-41300.
Morton et al. (2004) Diabetes 53: 931-938.
Ogawa et al. (1992) J. Clin. Invest. 90: 497-504.
Pitt et al., New England J. Med. (1999), 341: 709-719.
Pitt et al., New England J. Med. (2003), 348: 1309-1321.
Rajan et al. (1996) J. Neurosci. 16: 65-70.
Rask et al. (2001) J. Clin. Endocrinol. Metab. 86: 1418-1421.
Rauz et al. (2001) Invest. Ophthalmol. Vis. Sci. 42: 2037-2042.
Reaven (1993) Ann. Rev. Med. 44: 121-131.
Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1
Burns David M.
Chen Lihua
He Chunhong
Yao Wenqing
Zhuo Jincong
Fish & Richardson P.C.
Incyte Corporation
Powers Fiona T
LandOfFree
Modulators of 11-β hydroxyl steroid dehydrogenase type... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulators of 11-β hydroxyl steroid dehydrogenase type..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulators of 11-β hydroxyl steroid dehydrogenase type... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2729420